NCT03645642View on ClinicalTrials.gov

To Study the Safety and Efficacy of Midodrine With Albumin Versus Albumin Alone in Hepatic Hydrothorax

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2018

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions

Hepatic Hydrothorax

Interventions

DRUG

Midodrine

Midodrine 5 mg thrice daily

BIOLOGICAL

Albumin

Albumin 20g/l

DRUG

Diuretics

Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.

Trial Locations (1)

110070

Institute of Liver and Biliary Sciences, New Delhi

All Listed Sponsors

lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT03645642 - To Study the Safety and Efficacy of Midodrine With Albumin Versus Albumin Alone in Hepatic Hydrothorax | Biotech Hunter | Biotech Hunter